Revenue Performance - Total revenue for Q3 2024 increased by 5.8% to $88.8 million from $84.0 million in Q3 2023, driven by higher demand and new customer gains [2]. - For the full year 2024, revenue is expected to range from approximately $329 million to $331 million, representing a growth of about 4% to 5% over the previous year [6]. - Total revenue for the three months ended September 30, 2024 was $88,834,000, representing a 5.8% increase compared to $83,967,000 in the same period of 2023 [16]. - Sales revenue for Q3 2024 was $74.9 million, up from $68.0 million in Q3 2023, while rental revenue decreased to $13.9 million from $16.0 million [13]. Profitability and Loss - GAAP net loss for Q3 2024 was $6.0 million, significantly reduced from $45.7 million in Q3 2023 [4]. - The company reported a basic net loss per share of $0.25 for Q3 2024, compared to $1.97 in Q3 2023 [13]. - Comprehensive loss for Q3 2024 was $4.1 million, a significant improvement from $46.4 million in Q3 2023 [13]. - Net loss for the nine months ended September 30, 2024 was $26,131,000, significantly improved from a net loss of $75,894,000 for the same period in 2023 [15]. - The company reported a GAAP net loss of $26,131 for the nine months ended September 30, 2024, compared to a loss of $75,894 in 2023 [19]. - Non-GAAP adjusted net loss was $14,586 for the nine months ended September 30, 2024, down from $28,825 in 2023 [19]. - Diluted EPS for 2024 was $(1.11), compared to $(3.28) in 2023 [19]. Cost Management - Total gross margin improved to 46.5% in Q3 2024, up from 40.2% in Q3 2023, primarily due to lower raw material costs [3]. - Total operating expenses decreased by 39.0% to $49.1 million in Q3 2024 compared to $80.5 million in Q3 2023, largely due to a one-time goodwill impairment charge in the prior year [3]. - Adjusted EBITDA was positive at $0.5 million in Q3 2024, compared to a negative $5.5 million in Q3 2023 [4]. - Adjusted EBITDA for the three months ended September 30, 2024 was $460,000, compared to an adjusted EBITDA loss of $5,456,000 in the same period of 2023 [17]. Sales Breakdown - Business-to-business domestic sales increased by 35.1% to $23,352,000 for the three months ended September 30, 2024, compared to $17,288,000 in 2023 [16]. - The company reported a significant increase in business-to-business international sales, which rose by 26.2% to $32,328,000 for the three months ended September 30, 2024, compared to $25,613,000 in 2023 [16]. - Direct-to-consumer domestic sales decreased by 23.2% to $19,249,000 for the three months ended September 30, 2024, down from $25,072,000 in 2023 [16]. - Units sold increased from 35,400 in the three months ended September 30, 2023 to 43,900 in the same period of 2024, a growth of approximately 23.5% [16]. Cash and Assets - Cash, cash equivalents, marketable securities, and restricted cash totaled $124.3 million as of September 30, 2024, an increase of $3.0 million from Q2 2024, with no debt outstanding [5]. - Cash and cash equivalents decreased from $125,492,000 as of December 31, 2023 to $105,690,000 as of September 30, 2024, a decline of approximately 15.8% [14]. - Total assets decreased from $326,194,000 in December 31, 2023 to $306,172,000 as of September 30, 2024, a decline of approximately 6.1% [14]. - Total current liabilities remained relatively stable, decreasing slightly from $72,496,000 in December 31, 2023 to $72,396,000 as of September 30, 2024 [14]. Other Financial Metrics - Amortization of intangibles increased to $3,227 in 2024 from $284 in 2023 [19]. - Stock-based compensation decreased to $5,704 in 2024 from $8,484 in 2023 [19]. - Acquisition-related expenses were $784 in 2024, down from $1,981 in 2023 [19]. - Restructuring-related charges were $3,426 in 2023, with no corresponding charge in 2024 [19]. - Impairment charges were $32,894 in 2023, with no impairment charges reported in 2024 [19]. - The change in fair value of earnout liability was $1,830 in 2024, with no corresponding figure in 2023 [19]. - The effective tax rate for the adjustments was 0% [19].

Inogen, Inc. (INGN) has witnessed strong momentum in the past six months period. Shares of the company have surged 46.8% compared with 1.8% growth of the industry. The S&P 500 composite has risen 10% during the same time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment. Headquartered in Goleta, CA, Inogen develops, manufactures, and markets portable oxygen concentrators (POCs) used by patie ...

For the quarter ended June 2024, Inogen (INGN) reported revenue of $88.77 million, up 6.1% over the same period last year. EPS came in at -$0.24, compared to -$0.42 in the year-ago quarter. The reported revenue represents a surprise of +7.80% over the Zacks Consensus Estimate of $82.34 million. With the consensus EPS estimate being -$0.54, the EPS surprise was +55.56%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Inogen (INGN) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 55.56%. A quarter ago, it was expected that this produces oxygen concentrators for patients suffering from chronic respiratory conditions would post a loss of $0.76 per share when it actually produced a loss of $0.62, delivering a ...

Investing in small-cap stocks can be a gateway to high returns, mainly when these companies exhibit strong growth fundamentals and strategic market positioning. Here, the focus is on three stocks to buy under $10. The fundamentals behind these companies may diversify portfolios with high potential. These companies' financial performance and strategic initiatives explain why these small-cap stocks are poised for high gains. Source: Poetra.RH / Shutterstock.com The first one has consistently demonstrated impr ...

The renowned provider of POCs has a market capitalization of $212.4 million. The company projects 50.2% growth for 2024 and expects to witness continued improvements in its business. Inogen's P/S ratio of 0.7X compares favorably with the industry's 3.1X. Downsides The Zacks Consensus Estimate for second-quarter 2024 revenues is pegged at $82.3 million, suggesting a 1.6% decline from the year-ago reported number. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22.9%. DX ...

Inogen, Inc. (INGN) incurred an adjusted loss per share of 45 cents for first-quarter 2024, which was narrower than the adjusted loss per share of 63 cents in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 76 cents per share.GAAP loss per share for the quarter was 62 cents, narrower than the year-earlier loss of 88 cents per share.Revenues in DetailInogen registered revenues of $78 million for the first quarter, up 8.1% year over year. The figure surpassed the Zacks Consensus Esti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware 33-0989359 (State or other jurisdiction of i ...

Inogen (INGN) reported $78.03 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 8.1%. EPS of -$0.62 for the same period compares to -$0.63 a year ago.The reported revenue represents a surprise of +6.48% over the Zacks Consensus Estimate of $73.28 million. With the consensus EPS estimate being -$0.76, the EPS surprise was +18.42%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

GOLETA, Calif., – May 07, 2024 – Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2024. "We are pleased to be off to a solid start at Inogen in 2024. Looking forward, we remain focused on positioning the business for revenue growth, improving our operating discipline to drive long-term profitability, and investing in our innovation pipeline to broaden our produ ...